Summary
Management framed Alvotech as entering a launch inflection point, with quality remediation behind it and selective direct U.S. commercialization alongside continued capacity flexibility.
- December launches remain pivotal to reaching the upper end of the annual outlook, while production has been at full capacity since June.
- Fujifilm is intended to provide flexibility for demand upside; management said partner production should be gross-margin neutral.
- Management presented direct U.S. selling as a selective strategy for Hemlibra and Infliximab, not a shift from its global business-to-business model.
Guidance
- $700M$650–$700 million revenue for the year
- $220M$180–$220 million adjusted EBITDA for the year
- Positive cash flow in Q4
- High-dose Eylea U.S. submission most likely early 2028
- High-dose Eylea safety and efficacy study in the U.S. runs next year
- No massive investment expected over the coming five years or so
What analysts pressed on
- 01FDA approval risk: management cited prior full review, resolved CRL issues, and favorable recent inspections; another FDA inspection remains at FDA’s discretion.
- 02Fujifilm capacity and margins: management described the partner site as upside and service-level flexibility, with production expected to be gross-margin neutral.
- 03Direct U.S. commercialization: management said Hemlibra and Infliximab were selected strategically, while keeping the broader business-to-business model.
- 04Annual outlook confidence: manufacturing and shipping the strong order book before year-end are the main execution requirements; December approvals support the upper end.
- 05Funding needs: proceeds support launch working capital and R&D pace; management did not rule out opportunistic or strategic funding.
- 06Long-term margins and capacity: management expects margins to strengthen with launches but gave no peak margin or detailed capacity utilization target.
Notable disclosures
- 60%60% of U.S. Humira and Stelara markets have converted to biosimilars, and management said neither Alvotech product has peaked in sales.
- 20%Around 20% was management’s high-level estimate for Humira private-label share, which is difficult to track in IQVIA.
- The FDA CRL involved customer complaints and pharma-grade silicone in filling equipment; management said it removed the silicone.
- Management said its high-dose Eylea formulation differs from the branded formulation and believes it does not infringe patents, while acknowledging possible litigation.
- Management said no massive investment is needed over the coming five years or so, citing Iceland capacity and Fujifilm as support.
Risks raised
- Annual outlook depends on manufacturing and delivering the order book before year-end, with the upper end tied to successful December launches.
- FDA approval timing remains uncertain because FDA may require another inspection, and approval is not assured despite management’s confidence.
- Direct commercialization of Infliximab enters a competitive market, and management offered no expected share or launch economics.
- Further funding remains possible; management declined to rule out opportunistic or strategic financing.
- High-dose Eylea faces a U.S. safety and efficacy study next year, delaying the expected submission until early 2028.
Tone: Positive 0.68
Management expressed confidence in quality readiness, launch prospects, and funding the current growth plan, while acknowledging approval and execution dependencies.
Who spoke
Company
- Robert WestmanExecutive Chairman
Analysts
- Unidentified AnalystAnalyst, Morgan Stanley
Full transcript
Analyst questions are marked with a bar. Timestamps are into the recording.
Prepared remarks
Unidentified AnalystAnalyst, Morgan Stanley
So thank you for joining this session of the Morgan Stanley Global Healthcare Conference. I am Thibaut Woutran. I am part of the European Equity Research Team based in London. Before we start the session, I need to refer to important disclosures. Please see Morgan Stanley Research Disclosure website at www. morganscler. com backslash research disclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative. So for this session with Alvotech, I am delighted to have with me Robert Westman, Executive Chairman of Alvotech, and Balaji Prasad, Chief Strategy Officer for Alvotech. Thank you very much for joining us. Maybe before we start with the Q&A, if you want to start with some introductory comments on the situation at Alvotech, where we are today, and the outlook for the company.
Robert WestmanExecutive Chairman
Yeah, thanks. It's great to be here. And I think it's fair to say that we have seen a lot of involvement, positive development with the company last month. And first of all, we resubmitted our four PLAs for three products, which we have pending with FDA. And we are very hopeful that that will be approved by FDA by end of the year. We got filing or submission confirmation from FDA on biosimilar 20 view, both vial and pre-filled syrens, and we strongly believe that we are the first and hopefully first to market with both presentation in Europe and US going forward. We concluded FDA inspection end of July, general surveillance inspection, and that went well. We got a VA status, and we just concluded now EMA inspection last few days ago, and we We are not seeing any major observation there.
So overall, with the inspection of the facility, we are getting very hopeful and very kind of certain on approval, hopefully, in coming months or beginning of December. But in addition to that, we have seen we made a good license contract with Lotus. That's a contract which allows us for the first time to go direct ourselves in the US with M-Libra and Infinci, which is quite exciting.
And overall, I mean, a lot of other things happening within the firm. But overall, I think we are in a good position at a strong inflection point with all the coming launches.
Unidentified AnalystAnalyst, Morgan Stanley
Okay, amazing. Maybe we can start on what you just touched on, which is the sort of evolution of your commercial model and Alvotech taking a more direct role in commercializing products in the U. S. I mean, historically, you've been through commercial partner. So maybe if you can sort of go through what's driving this evolution of the strategy.
Are there specific assets or therapeutic categories that are best suited for a direct commercial approach from Alvotech?
Robert WestmanExecutive Chairman
Yeah, I think it's a good question. I mean, overall, our model is business to business globally. And in this particular case, with those two products, we felt those two were strategically well geared to be marketed directly by AlvoTech. So even we, as I said, our model is business to business. is if you take, for instance, Hemlibra, which is north of $6 billion product, it's a very limited patient pool, if you will, and more targeted to hemophilia patient treatment centers, if you will.
And so on that end, it felt like in a wheelhouse of Alvotech, being able to assemble a small group of team to market the product.
And so that was an exciting opportunity for us. Of course, the concept is being able to capture more of the value chain, if you will. So quite exciting. So it was more strategic approach with selecting two products, which we felt could be easier to approach the market with. The team has been in the market, including myself, in the U. S. market over 20 years. So we know the channels, we know the players.
And so overall, it's not the overall change in how we think about our marketing, but we felt we were in part of our journey or we were in a time of our life where this was a natural next step for a strategic selected product. It might well be that we have a few more products like this coming in the U. S. going forward.
Unidentified AnalystAnalyst, Morgan Stanley
Okay. So rationale is clear for Hamli Bar, but Infindy is probably more sort of a challenging place to go in.
I mean, PD1 and PD1 are probably going to be quite competitive. So here as well, do you think sort of setting up a team is going to be what you're going to do, or is there a different approach for this one?
Robert WestmanExecutive Chairman
No, I think, again, it's still quite targeted, if you will, and the channels are of course a bit different from the big three PPMs as you know and we have worked with some of those in the past clearly and we have launched oncology products not through AlvoTech but through other portfolio companies in the past so we felt still being oncology that this could be a decent fit for AlvoTech to market themselves also.
Unidentified AnalystAnalyst, Morgan Stanley
Okay, amazing. That's very clear. And the other relatively recent development is the announcement of the second manufacturing sourcing from Fujifilm to add a US-based multi-product manufacturing capacity from next year. How much of this capacity is intended as redundancy capacity with what you have in Reykjavik, and how much is sort of incremental growth from this capacity?
Robert WestmanExecutive Chairman
Yeah, I think, I mean, overall, we are end-to-end by a similar company. We are selling what we basically develop and manufacturing, so everything we have in our portfolio is in-house developed. So Alvotek, I believe, has one of the broadest own in-house developed portfolio pipeline in the industry. So overall, we felt having a second source of some of the product would allow us to be more flexible.
We have, of course, invested dramatically into our manufacturing sites, if you will. I think our investment is north of half a billion dollars, if you will. So we have pretty substantial capacity, but we also are seeing a lot of our approvals coming through. And there are not many companies with so many BLAs on file, which are going to be approved in short time frame. So we felt that having the flexibility to meet upside potential extra demands, being able to maintain a strong service level, it would be important or very important to have alternative sites. So we had a conversation with different potential partners. Fujifilm has a very strong track record in the U. S. and so it came kind of natural to us to sign up with them.
So I think to answer the question, we will still allocate manufacturing to optimize the Reykjavik which is our main facility and utilize that facility we have invested in and having a strong capacity and partner in Fuji to meet demand and potential upsides when they source themselves if you will.
Unidentified AnalystAnalyst, Morgan Stanley
Okay amazing and when we think about the impact on the P&L in terms of gross margin do you expect that that this is going to be visible in the next few years?
Robert WestmanExecutive Chairman
Yeah, I mean, we will see that, as I mentioned, the company is at an inflection point. We have been growing quite a bit throughout when we launched the first product into market. I mean, we are less than three years into commercial marketing, if you will, into US market, the biggest one. So we are fairly young as a commercial organization, if you will. So we will see multiple products coming to market, which means that we should be seeing a strong growth continue going forward. And secondly, if you look at the gross margin, it should be pretty neutral whether products are produced in-house or with a partner like Futsifil.
Unidentified AnalystAnalyst, Morgan Stanley
Okay, that's clear. You touched a little bit on the resubmission of the BLA, so ALEA, Prolia, Exgeva, and two presentations of Symfony in the US. So there was an FDA inspection. It closed with, as you mentioned, a voluntary action indication. Can you just sort of help us assess is there any risk remaining on the approval and how confident are you that this submission will go through and sort of what makes you confident?
Robert WestmanExecutive Chairman
Yeah, so overall, so our PLAs were fully reviewed by FDA, which we resubmitted without any observation, if you will, so the PLAs have been kind of passed the test before, which are now resubmitted. The observation were partly facility related.
We think we have spent a lot of resources and energy to continue to evolve our quality system. I mean, again, company being young commercially, but we still are seeing or continuing to invest into our quality system. and production process, if you will. The company today is approved by all major health authorities in the world. We just closed out IMA, the European Health Authorities, an inspection last week, and that inspection went extremely well.
We closed out the July inspection with VA status, and we continue to evolve the quality system if you will. So we believe that whether FDA comes in for another inspection before they give us approval or not, we as a company, organization, we are well prepared and ready for that. So we are very confident that we have a good shot at getting approval this time around.
Unidentified AnalystAnalyst, Morgan Stanley
So just to confirm, you're not sure yet the FDA will require another inspection?
Robert WestmanExecutive Chairman
No, we are not fully because FDA is at discretion of FDA. I mean they just finished the inspection. As I said, it was closed out in July, so I think it's not absolutely certain that they will come. But either or, I mean it will be fine with us.
Unidentified AnalystAnalyst, Morgan Stanley
Okay, amazing. And then you touched a little bit on this, but what structural changes have you made to the manufacturing process, the quality process, you know, beyond just sort of resolving the specific observation?
Robert WestmanExecutive Chairman
Yeah, I mean, from the inspection where we got, so we have been producing for US, we have never had any product issues in the US, that we didn't get approval for three products which we resubmitted, so we continue to manufacture for the US market successfully. Overall, there were a couple of items which FDA pointed out when they gave us a CRL.
Actually, it was two issues which we believe we have addressed very well. One was related to customer complaints, the other one using a pharma-grade silicone in our filling machine, which has been used last 20 years in the industry and we have simply removed that. So I think when it comes to the pilot that we received and preparation from FTA, I mean, we always look holistically at what we are doing. We don't dive into one specific issue.
We should be well prepared if you want.
Unidentified AnalystAnalyst, Morgan Stanley
Okay, amazing. That's very clear. And so moving on to your portfolio and your pipeline, maybe starting with US ALEA. So the market formation should be around the first quarter of this year, based on when the IP goes away. For Alvotech specifically, do you expect the approval to be gated by the IP or by your own approval, assuming the FDA gives you clearance for US ALEA?
Robert WestmanExecutive Chairman
Yeah, we have a settlement with Regeneron. which is allowing us to basically launch up on approval in December. So we have seen Amtian, of course, been first to market, if you will, and over a year been able to convert. I believe they are close to 40% from the brand sales. And I believe that Alvotech with two other players are coming in now. So we feel pretty excited about the opportunity. It's close to a $4 billion market. So we are still seeing the market exciting even though this time around we are not first in. But we are in the second wave now, meaning Amtian was the first. So pretty good, strong opportunity in this one.
Unidentified AnalystAnalyst, Morgan Stanley
Amazing. And as a follow-on to Elia, you are working on the high dose formulation, the 8 mg. Can you update us on the regulatory status? You are filing in some regions in 2026.
Maybe starting here, which sort of major regions can you file this year for the high dose?
Robert WestmanExecutive Chairman
High dose is a very interesting program for us. We started developing high dose before the brand launched 8 milligrams. so when the brand launched we had one of our formulation matching the brand what we did is the formulation of 2mg to 8mg is not fully identical so we made sure that 8mg was a bit different because of the IP and so the European Health Authority They believe that no efficacy or safety study was required.
So we are working hard on filing this year. And basically in the U. S. we are based on requirement by FDA. We are running a safety and efficacy study which will be basically running next year, if you will. So, submission most likely early 28.
Unidentified AnalystAnalyst, Morgan Stanley
Okay, and to confirm on the high dose, because there were slightly different molecules, this is going to be the approval that's going to condition the launch, is not a residual IP situation on the high dose?
Robert WestmanExecutive Chairman
No, I mean, we believe that we are in a very strong position with IP, and especially with the final tweak we did to the formulation, we are very confident that we are not infringing any of the patents. All IP situations are partly complex but they can also be fairly simple when you know the way you going and that in this particular case we know well where we where we are and we think we are in a good position I doesn't mean that but we will not have some litigation challenges or that they might be sued but we we are in a good position to bring the product to market. And maybe to say that also, I mean, we are also with a safety device, as you know, the height dose in Europe is 80% with OccuClick and safety device, 20% is the vial.
And I think we are the only one I know of, at least, which have developed the safety device, which is important.
Unidentified AnalystAnalyst, Morgan Stanley
Okay, that's clear. Moving on to Symfony in the US, so I think the only competitor here is BioTerra. They are gearing up for launch in the fourth quarter. So if your CRL is resolved, do you think you can launch around the same time? Is there a remaining IP challenge, as I think BioTerra is dealing with a lawsuit from Johnson & Johnson on Symfony?
Robert WestmanExecutive Chairman
Yes, I think on IP again, without going into that in specifics, we are in a very strong legal position or IP position with the products and basically the patent put forward by J&J potential PI. We are absolutely certain we are not infringing that. So we think that launch should be at approval. We have of course launched the product into Europe and we have been on the market since late last year. BiotheraWars got approval which you mentioned which is the only known other party with the product and they have had their own GMP challenges so they have not been on the market last I believe nine or ten months so we remain it remains to be seen whether we are in the same wave at launch in US as they are or if you managed to get there first.
Unidentified AnalystAnalyst, Morgan Stanley
Okay, amazing. And maybe another important pipeline asset you're working on is the NTVO biosimilar, where you find in Europe, in the US, and I guess here the question is on the timing of launch in both regions and what the IP situation is for NTVO. And PVO, yeah.
Robert WestmanExecutive Chairman
So, again, we feel strongly about it and we think this is a near-term opportunity we would not go into details on launch timing in different countries but again having a strong position and we think we'll be in already launched in in a few markets towards 27.
Unidentified AnalystAnalyst, Morgan Stanley
Amazing. And then so we mentioned some of the sort of key and closest launch in your pipeline. What other asset would you highlight within your pipeline in the next wave of development? You know maybe Simsia or anything else you want to sort of point out as being very attractive in your pipeline?
Robert WestmanExecutive Chairman
Yeah, I think of course Antivio and Haidos ELEA are two extremely exciting opportunities, Antivio being 7 billion plus dollars, where there will be a very limited competition. We believe that it might be first to market globally with both the vial and pre-filterings, if you will.
Other opportunities, I mean, we have seen, as you mentioned, Simcia, where we are seeing very few companies engaged in that product. Elaris, which we think we are in a very strong position. Huts, where we are in a very strong position. K2, even though there is a lot of players in that, it's a co-development with Dr. Redis. I think our company will be extremely competitive when it comes to cost of goods and being able to stay in the market.
So these are all kind of fairly near-term or slightly mid-term opportunities we are seeing.
Unidentified AnalystAnalyst, Morgan Stanley
Okay, amazing. So we went through pipeline, maybe moving on to sort of commercial assets. You mentioned the launch of the Symfony Biosimla in Europe. Around the same time, you also launched Ailea and Denosumab. So overall, how is the uptake going in terms of these ex-US opportunities that you launched at the end of last year?
Robert WestmanExecutive Chairman
Yeah, I mean, we are extremely excited about especially Symfony being alone in the markets. And we have seen launches in over 10 European countries, including being first in Japan. And very strong markets here in many of the countries. We are seeing very strong uptake in Germany, in Spain. And we continue, or our commercial partner continues to roll out the product. So overall, I mean, strong conversion and very exciting opportunity. Same with Eilea. I mean, it has been rolled out in over time countries and advanced, which is our commercial partner doing extremely well there.
Unidentified AnalystAnalyst, Morgan Stanley
Okay, amazing. Maybe turning to the U. S. and Umeera, can you give us some insight on the commercial performance of your Umeera biosimilar in the U. S.? maybe if you can make a distinction between private label channel on one side and the rest of the commercial channel and from here as well how far do you expect Biosimilar penetration will go and what kind of market share do you think you can ultimately achieve with Humira Biosimilar in the US yeah I think I mean Humira had a little slow start than some of the others but still Today we have seen 60% conversion from the brand to Biosimilas, which I think is a strong and good position to be in.
Robert WestmanExecutive Chairman
Teva, our commercial partner, is having the second largest market share in the US. And we are seeing that they are growing their share and volume quarter by quarter. so we are extremely happy to be having Tevas our commercial partner, if you will.
With the private label, as you might know, private label is not really part of IQVIA, was not really at the beginning, so it's a little bit more complicated to track how private label is doing. but my high level estimate would be around 20% so the biosimilar part is 80% or biosimilar plus branded part if you will so we believe that the growth is happening on the biosimilar side more than a private label site, if you will.
Unidentified AnalystAnalyst, Morgan Stanley
Okay, that's clear. And staying on Yumeirah, but looking at ex-US, here it's been partnered to your partner Stada, and obviously it's been a harder market to go into later and after competitors. Is there room to accelerate market share gain here, or should we have moderate expectations for Yumeirah outside of the US?
Robert WestmanExecutive Chairman
No, I mean, Humira, we came in with a high dose, but the market had already formed a few years before we came. We stopped developing low dose when we saw that the brand switched to other high So we launched basically the high right into a very formed biosimilar low market So I think in that environment, Stara has done a good job. And with Stellara, we are seeing mostly second or third position in all the key markets in Europe, and we are still going to see, I think, more volume coming our way forward.
Unidentified AnalystAnalyst, Morgan Stanley
Okay, that's great. Strong performance of Stellara Express. And Stellara US, similar question to you, Mira, penetration of biosimilars, how much more room to go? What is your market share here? And to what extent is private label playing any role for Stellara compared to what we're seeing with Umeara?
Robert WestmanExecutive Chairman
Yeah, I think Stellara with the private label is very small, if anything. Teva is in top three to four with Stellara, I believe, and is gaining share there also. and the market has converted around 60% so the Stellara market converted two years faster I can say they are at the same place as Humira if you will so overall the market is still exciting we are seeing overall holistically for those two products for Alvotech that we have not peaked in sales so we are looking forward to continue with those products and we will see some growth going forward on those two molecules if you will.
Unidentified AnalystAnalyst, Morgan Stanley
Okay, that's great. If we move to your financials and your guidance, so for this year you're guiding for $650 to $700 million of revenues, between $180 and $220 million of adjusted EBITDA and positive cash flow in Q4. So you told us the guidance is backhanded to Q4. Can you just touch a bit on your level of confidence in achieving this? Are there any sort of key milestones that you need to reach on the business to basically be able to meet the guidance?
Robert WestmanExecutive Chairman
Yes, so overall we mentioned when we gave out the guidance that the higher end was geared towards successful launch in December for the pending products. products but I think overall I mean the main I would say what we are working towards to hit the guidance as it is presented is basically our manufacturing as we speak we since June we have We have gone to full capacity in our production. It's going very well to meet all the demands. The order book is strong. So basically deliver the question was basically what are the challenges or opportunities to hit the guide that is basically mainly hitting the order book and deliver the products before year end. I think the company is in a good place to meet that whole or good portion.
And then, of course, the milestones, revenues, which both will come with approval. And then we are always very busy, active licensing out. But overall, I mean, we feel that the company is in a good place to find itself lending in the guidance range, if you will.
Unidentified AnalystAnalyst, Morgan Stanley
Okay, amazing. And if you can just touch a bit maybe on sort of funding, capital need. So you recently raised $165 million in equity. You secured a $75 million terms facility.
Can you come back on, you know, what this funding is going to be used for? And, you know, from here, do you expect to sort of need further funding on the line, or do you feel like you are capitalized for the future?
Robert WestmanExecutive Chairman
Yeah, I think so overall, I mean, AlvoTech, we are having one of the broader portfolio as mentioned and then I mean when you look at companies which are doing the in-house development. We did the funding grant mostly because we wanted really to continue the pace we are on. We feel the opportunities we are building today for future growth is extremely important and there is an amazing opportunity we are in front of being able to continue the pace in R&D we are in. So most of the funding was secured to make sure that both working capital for the launches and the R&D we could keep that pace. Overall I would never rule out opportunistic or strategic funding if you will, but that just remains to be seen.
Unidentified AnalystAnalyst, Morgan Stanley
That makes sense. And maybe thinking about the profitability in particular long term, if I look at our 26 guidance, it suggests an EBITDA margin of around 30% this year, and your previous long-term guidance was suggesting the business could achieve sort of 40-45% EBITDA margin. maybe the margin. So should we see this as, you know, at the potential long-term margins for the business? What could be your peak margin in the long term once you've achieved more scale and you have a broader portfolio on the market?
Robert WestmanExecutive Chairman
Yeah, so the company, of course, is coming out of 12 months where we had to slow down to make sure that we had the proper response to FDA and we would be ready to do all the launches we wanted. we are out of that phase now and with a slowdown of course the company did not have the same throughput through the facility as it should have if it would be producing at full capacity so I think with the new launches coming in December we should be in a very strong position to continue to grow and strengthen the EBITDA margin going forward and And I mean, we are, of course, looking at some of the benchmark in the industry, whether it is Samsung or Celtrion.
They are at the level which you are mentioning. And go forward, we have a similar pipeline as Samsung. So we believe that we should not be very much different from the EBITDA margin those companies do have today.
Unidentified AnalystAnalyst, Morgan Stanley
Okay. That's very clear. And maybe a final question on the capex and capital intensity. You know, the capex so far, I mean, over the last three years, has been very light, considering that, you know, you're primarily R&D and manufacturing business. So how far can the current capacity you have sort of carry you for the future? Obviously, there is a Fujifilm capacity on top.
But should we expect AvaTech to enter another capex cycle at some point to build more capacity to address the biosimilar opportunities?
Robert WestmanExecutive Chairman
Yeah, it's a good question. I mean, as I mentioned, we have invested a lot into the facility. As I mentioned, so the facility is fairly new. And so on the facility itself, it's not requiring a major investment going forward. We still can increase the capacity in Iceland. We still have both one suite for drug product and one suite for drug substance, which we will be fitting out. But most of the equipments and investment there, at least the big parts of it, building out the facility has been done.
And then, of course, we have Futsi, as you mentioned. So we believe that with this combination, the company does not need to go into a massive investment in coming five years or so, I believe.
Unidentified AnalystAnalyst, Morgan Stanley
Okay. I think we're at the end of the time. So, Robert Balaji, thank you very much for joining us today at the conference.
Robert WestmanExecutive Chairman
Yeah. Thank you so much. Thank you.
Unidentified AnalystAnalyst, Morgan Stanley
Thank you for listening, Stibor. Thank you.
Other Alvotech earnings calls
- Q3 2026 earnings call
Management framed Q3 as a gradual supply recovery, with October FDA approvals improving capacity and productivity ahead of a potentially pivotal fourth quarter.
Nov 12, 2026Mildly positive0.35 - Q2 2026 earnings call
Management framed the half as a supply-constrained transition, with manufacturing restored to plan and execution now focused on rebuilding inventory and preparing launches.
Aug 20, 2026Positive0.55 - FY 2026 earnings call
Management framed Alvotech as entering a launch-driven growth inflection, with facility remediation and first-wave positioning supporting its near-term pipeline.
Jun 08, 2026Confident0.78 - Q4 2025 earnings call
Management framed 2026 as an execution year, prioritizing FDA remediation, reliable supply, partner-led launches, and selective manufacturing diversification.
Mar 19, 2026Mildly positive0.35 - Q3 2025 earnings call
Management framed the call around a delayed Symphony approval and a deliberate production slowdown, while emphasizing that launch momentum and 2026 growth remain intact.
Nov 13, 2025Mildly positive0.20
About this transcript
The summary, guidance, analyst focus, and tone are automated and should be checked against the call before being relied on. Names and figures can be misheard. Listen to the replay.